-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
LUSTER-1 and -2: Two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma
Barbara Knorr
Protocol: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Cancer cachexia: an unmet need in cancer treatment
Ozkan Kanat, Bert H O ™Neil
Commentary: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vosaroxin for acute myeloid leukemia
Joelle El-Amm & Imad A Tabbara
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunotherapy & cancer - making the past prologue Immunotherapeutic combinations for cancer
Susan F Slovin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation
-
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Research Update: Clinical Investigation